Abstract: Traditional treatments for chronic actinic dermatitis (CAD) include topical glucocorticoids, calcineurin inhibitors; for severe cases, systemic treatments such as oral hydroxychloroquine, corticosteroids, and immunosuppressants are optional. However, due to suboptimal therapeutic outcomes, patients often require long-term medication, leading to numerous adverse effects. In recent years, Janus kinase (JAK) inhibitors have demonstrated significant efficacy in refractory CAD. We administered abrocitinib to three patients with chronic actinic dermatitis, two of whom showed marked improvement within two weeks, and one achieved complete remission after four weeks, with no infection-related adverse events observed. Two of the patients followed a tapering regimen of 50 mg/day and maintained remission during follow-up periods of six and three months, respectively. Furthermore, we summarized a total of 16 cases of JAK inhibitor treatment for CAD, aiming to provide valuable clinical references and practical guidance.

Key words: JAK inhibitors, abrocitinib, chronic actinic dermatitis, rapid improvement